The commercialisation of bio-synthesised cannabidiol could be on the horizon following the announcement by Amyris that it will be forming a new partnership to focus on “cannabinoid development”. The California-based company is best known for creating synthetic sweeteners and medicines from sugars using a yeast-based process, and it is thought it will do the same […] ...
Restricted content. Do you want to read more?
Register
Sign up NOW for 7 days FREE TRIAL and access our briefings section
This report will enable you to identify pricing differences and the range of pricing for product types across different markets, understand possible reasoning for pricing differences across different markets, and identify price points for strategy development and price setting.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
